ES2380654T3 - Tableta de desintegración rápida que comprende un ingrediente activo lábil en medio ácido - Google Patents
Tableta de desintegración rápida que comprende un ingrediente activo lábil en medio ácido Download PDFInfo
- Publication number
- ES2380654T3 ES2380654T3 ES01999360T ES01999360T ES2380654T3 ES 2380654 T3 ES2380654 T3 ES 2380654T3 ES 01999360 T ES01999360 T ES 01999360T ES 01999360 T ES01999360 T ES 01999360T ES 2380654 T3 ES2380654 T3 ES 2380654T3
- Authority
- ES
- Spain
- Prior art keywords
- active ingredient
- tablet
- labile
- mixture
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract 12
- 239000002253 acid Substances 0.000 title claims abstract 7
- 239000007898 rapid-disintegration tablet Substances 0.000 title 1
- 230000002378 acidificating effect Effects 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 8
- 102000006270 Proton Pumps Human genes 0.000 claims abstract 7
- 108010083204 Proton Pumps Proteins 0.000 claims abstract 7
- 239000003112 inhibitor Substances 0.000 claims abstract 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 7
- 239000007884 disintegrant Substances 0.000 claims abstract 6
- 239000011159 matrix material Substances 0.000 claims abstract 5
- 239000012188 paraffin wax Substances 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 239000007787 solid Substances 0.000 claims abstract 5
- 229920002472 Starch Polymers 0.000 claims abstract 4
- 239000000314 lubricant Substances 0.000 claims abstract 4
- 235000019698 starch Nutrition 0.000 claims abstract 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract 3
- 239000000194 fatty acid Substances 0.000 claims abstract 3
- 229930195729 fatty acid Natural products 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000783 alginic acid Substances 0.000 claims abstract 2
- 235000010443 alginic acid Nutrition 0.000 claims abstract 2
- 229920000615 alginic acid Polymers 0.000 claims abstract 2
- 229960001126 alginic acid Drugs 0.000 claims abstract 2
- 150000004781 alginic acids Chemical class 0.000 claims abstract 2
- 239000002775 capsule Substances 0.000 claims abstract 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract 2
- 230000037406 food intake Effects 0.000 claims abstract 2
- 239000004005 microsphere Substances 0.000 claims abstract 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 2
- 239000011734 sodium Substances 0.000 claims abstract 2
- 229910052708 sodium Inorganic materials 0.000 claims abstract 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract 2
- 239000008107 starch Substances 0.000 claims abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 4
- 229960005019 pantoprazole Drugs 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- -1 fatty acid ester Chemical class 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000373 fatty alcohol group Chemical group 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 229960003174 lansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 229940126409 proton pump inhibitor Drugs 0.000 claims 1
- 239000000612 proton pump inhibitor Substances 0.000 claims 1
- 229960004157 rabeprazole Drugs 0.000 claims 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00126807 | 2000-12-07 | ||
| EP00126807 | 2000-12-07 | ||
| PCT/EP2001/014340 WO2002045694A1 (en) | 2000-12-07 | 2001-12-06 | Rapidly disintegrating tablet comprising an acid-labile active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2380654T3 true ES2380654T3 (es) | 2012-05-17 |
Family
ID=8170591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01999360T Expired - Lifetime ES2380654T3 (es) | 2000-12-07 | 2001-12-06 | Tableta de desintegración rápida que comprende un ingrediente activo lábil en medio ácido |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7147869B2 (enExample) |
| EP (1) | EP1341528B1 (enExample) |
| JP (1) | JP2004514737A (enExample) |
| KR (1) | KR20030072555A (enExample) |
| CN (1) | CN100335040C (enExample) |
| AT (1) | ATE541564T1 (enExample) |
| AU (1) | AU2002221939A1 (enExample) |
| BR (1) | BR0115986A (enExample) |
| CA (1) | CA2430829C (enExample) |
| CY (1) | CY1112615T1 (enExample) |
| DK (1) | DK1341528T3 (enExample) |
| ES (1) | ES2380654T3 (enExample) |
| PT (1) | PT1341528E (enExample) |
| SI (1) | SI1341528T1 (enExample) |
| WO (1) | WO2002045694A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7988999B2 (en) * | 2000-12-07 | 2011-08-02 | Nycomed Gmbh | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
| JP5009482B2 (ja) * | 2000-12-07 | 2012-08-22 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤 |
| UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
| IL159584A0 (en) * | 2001-07-16 | 2004-06-01 | Astrazeneca Ab | Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| ES2335498T3 (es) | 2003-03-10 | 2010-03-29 | Nycomed Gmbh | Nuevo proceso para la preparacion de reflumilast. |
| CL2004000983A1 (es) | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
| PE20050150A1 (es) | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
| EP1768668A2 (en) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| US8057820B2 (en) * | 2004-10-08 | 2011-11-15 | Mcneil-Ppc, Inc. | Enteric coated aspirin granules comingled with binder |
| US8758814B2 (en) | 2004-10-08 | 2014-06-24 | Mcneil-Ppc, Inc. | Chewable enteric coated aspirin tablets |
| EP2258350B1 (en) | 2005-03-16 | 2014-12-24 | Takeda GmbH | Taste masked dosage form containing roflumilast |
| FR2885526B1 (fr) * | 2005-05-13 | 2007-07-27 | Flamel Technologies Sa | Medicament oral a base d'inhibiteur de pompe a protons |
| CN100431526C (zh) * | 2005-11-07 | 2008-11-12 | 上海艾力斯医药科技有限公司 | 一种酸敏感型药物的快速崩解片剂 |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8425935B2 (en) * | 2005-12-21 | 2013-04-23 | Basf Se | Pharmaceutical formulation for producing rapidly disintegrating tablets |
| WO2008148742A2 (de) * | 2007-06-06 | 2008-12-11 | Basf Se | Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten |
| US8568780B2 (en) * | 2007-06-06 | 2013-10-29 | Basf Se | Pharmaceutical formulation for the production of rapidly disintegrating tablets |
| BRPI0818286A2 (pt) * | 2007-10-12 | 2020-08-11 | Takeda Pharmaceuticals North America, Inc. | métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento. |
| DE102010011421A1 (de) * | 2009-03-19 | 2010-09-30 | Schaeffler Technologies Gmbh & Co. Kg | Schaltbarer Schlepphebel eines Ventiltriebs einer Brennkraftmaschine |
| WO2010122583A2 (en) | 2009-04-24 | 2010-10-28 | Rubicon Research Private Limited | Oral pharmaceutical compositions of acid labile substances |
| WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| US20130052278A1 (en) * | 2010-03-11 | 2013-02-28 | Rich Vitamins Llc | Quick dissolve nutritional powder |
| EP2583673A1 (en) * | 2010-10-14 | 2013-04-24 | Deva Holding Anonim Sirketi | Coating of cetyl myristate and/or cetyl palmitate particles |
| EP2441446A1 (en) * | 2010-10-14 | 2012-04-18 | Deva Holding Anonim Sirketi | Using of superdisintegrants in cetyl myristate and/or cetyl palmitate formulations |
| CA2823628A1 (en) | 2011-01-05 | 2012-07-12 | Hospira, Inc. | Spray drying vancomycin |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| CN120585773B (zh) * | 2025-08-06 | 2025-11-07 | 广州仁恒医药科技股份有限公司 | 一种盐酸米诺环素胶囊及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3065142A (en) * | 1958-07-30 | 1962-11-20 | Armour Pharma | Gastric resistant medicinal preparation |
| US4006227A (en) * | 1973-11-15 | 1977-02-01 | Gallegos Alfred J | Compositions and methods for fertility control |
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
| US5380535A (en) * | 1991-05-28 | 1995-01-10 | Geyer; Robert P. | Chewable drug-delivery compositions and methods for preparing the same |
| EP0587744B1 (en) * | 1991-05-28 | 2003-07-16 | McNEIL-PPC, Inc. | Chewable drug-delivery composition |
| PT745382E (pt) * | 1994-01-31 | 2004-04-30 | Yamanouchi Pharma Co Ltd | Forma moldada por compressao com solubilidade intra-oral e processo para a sua producao |
| SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| WO1996001623A1 (en) | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | Multiple unit tableted dosage form i |
| SE512835C2 (sv) | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
| JP4939680B2 (ja) * | 1997-05-27 | 2012-05-30 | 武田薬品工業株式会社 | 固形製剤 |
| NZ505123A (en) * | 1997-12-19 | 2003-07-25 | Smithkline Beecham Corp | Process for manufacturing bite-dispersion tablets by compressing medicaments and other ingredients into granulates then compressing the granulates and other ingredients into tablets, and the tablets thereof |
| SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
| WO1999059544A2 (en) * | 1998-05-18 | 1999-11-25 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
| ATE481090T1 (de) * | 1998-07-28 | 2010-10-15 | Takeda Pharmaceutical | Leicht zerfallende feste zubereitung |
| SE9803240D0 (sv) * | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
| JP4980527B2 (ja) * | 1999-06-07 | 2012-07-18 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 酸に不安定な活性化合物を含有する新規の製剤および投与形 |
| DE19925710C2 (de) * | 1999-06-07 | 2002-10-10 | Byk Gulden Lomberg Chem Fab | Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer |
-
2001
- 2001-12-06 DK DK01999360.9T patent/DK1341528T3/da active
- 2001-12-06 BR BR0115986-0A patent/BR0115986A/pt not_active Application Discontinuation
- 2001-12-06 PT PT01999360T patent/PT1341528E/pt unknown
- 2001-12-06 US US10/433,397 patent/US7147869B2/en not_active Expired - Fee Related
- 2001-12-06 AU AU2002221939A patent/AU2002221939A1/en not_active Abandoned
- 2001-12-06 KR KR10-2003-7007557A patent/KR20030072555A/ko not_active Ceased
- 2001-12-06 EP EP01999360A patent/EP1341528B1/en not_active Expired - Lifetime
- 2001-12-06 SI SI200131011T patent/SI1341528T1/sl unknown
- 2001-12-06 JP JP2002547480A patent/JP2004514737A/ja active Pending
- 2001-12-06 ES ES01999360T patent/ES2380654T3/es not_active Expired - Lifetime
- 2001-12-06 WO PCT/EP2001/014340 patent/WO2002045694A1/en not_active Ceased
- 2001-12-06 CN CNB018202594A patent/CN100335040C/zh not_active Expired - Fee Related
- 2001-12-06 AT AT01999360T patent/ATE541564T1/de active
- 2001-12-06 CA CA2430829A patent/CA2430829C/en not_active Expired - Fee Related
-
2012
- 2012-04-09 CY CY20121100345T patent/CY1112615T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE541564T1 (de) | 2012-02-15 |
| CN100335040C (zh) | 2007-09-05 |
| JP2004514737A (ja) | 2004-05-20 |
| EP1341528A1 (en) | 2003-09-10 |
| CN1479613A (zh) | 2004-03-03 |
| SI1341528T1 (sl) | 2012-05-31 |
| US7147869B2 (en) | 2006-12-12 |
| AU2002221939A1 (en) | 2002-06-18 |
| EP1341528B1 (en) | 2012-01-18 |
| CA2430829C (en) | 2010-06-22 |
| WO2002045694A1 (en) | 2002-06-13 |
| US20040110661A1 (en) | 2004-06-10 |
| CY1112615T1 (el) | 2016-02-10 |
| CA2430829A1 (en) | 2002-06-13 |
| PT1341528E (pt) | 2012-03-20 |
| BR0115986A (pt) | 2003-12-23 |
| HK1062264A1 (zh) | 2004-10-29 |
| DK1341528T3 (da) | 2012-03-26 |
| KR20030072555A (ko) | 2003-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2380654T3 (es) | Tableta de desintegración rápida que comprende un ingrediente activo lábil en medio ácido | |
| ES2392684T3 (es) | Forma de administración que comprende un compuesto activo lábil a ácidos | |
| ES2246238T3 (es) | Nueva preparacion y forma de administracion que comprende un inhibidor de las bombas de protones labil en medio acido. | |
| ES2375269T3 (es) | Preparado farmacéutico en forma de una pasta que comprende un ingrediente activo l�?bil ante los �?cidos. | |
| ES2403238T3 (es) | Preparación farmacéutica en forma de una suspensión que comprende un ingrediente activo lábil en medio ácido | |
| HK1068557A (en) | Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient | |
| CZ20002122A3 (cs) | Léková forma |